Close

Rigel Pharmaceuticals (RIGL) PT Lowered to $7 at BMO Capital Jan 13, 2022 08:36AM
Rigel Pharmaceuticals (RIGL) PT Raised to $9 at BMO Capital Feb 18, 2021 01:19PM
Rigel Pharmaceuticals (RIGL) COVID-19 Treatment Could Be Potential Catalyst - BMO Sep 17, 2020 10:04AM
Investigator-Led Tavalisse Study in COVID-19 Positive for Rigel Pharmaceuticals (RIGL) - BMO Jul 14, 2020 01:55PM
Rigel Pharmaceuticals (RIGL) PT Raised to $11 at BMO Capital Jan 23, 2019 01:15PM


Dec 5, 2018 07:30AM Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City
Jun 20, 2018 07:07AM BMO Capital Remains Bullish on Rigel Pharma (RIGL); Says Tavalisse Launch is On Track
May 2, 2018 01:12AM Rigel Pharmaceuticals (RIGL) PT Raised to $10 at BMO Capital Following Q1 Earnings Beat
Apr 20, 2018 05:34AM Rigel Pharma (RIGL) Prices 16M Share Common Offering at $3.90/Sh
Apr 19, 2018 07:31PM Rigel Announces Pricing Of Public Offering Of Common Stock
Apr 18, 2018 04:36PM Rigel Pharma (RIGL) Announces Proposed 15M Share Common Offering
Apr 18, 2018 04:34PM Rigel Announces Proposed Public Offering Of Common Stock
Apr 17, 2018 05:06PM Rigel Pharmaceuticals (RIGL) PT Raised to $8 at BMO Capital on FDA Approval
Apr 3, 2018 01:33PM Rigel Pharmaceuticals (RIGL) Weakness 'Overdone' - BMO
Apr 2, 2018 05:40PM BMO Capital Bullish on Rigel (RIGL) into Tavalisse PDUFA
Oct 10, 2017 04:01PM Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
Oct 5, 2017 05:43AM Rigel Pharma (RIGL) Prices 18.1M Share Common Offering at $3.35/Sh
Oct 4, 2017 10:36PM Rigel Announces Pricing Of Public Offering Of Common Stock
Oct 3, 2017 04:04PM UPDATE: Rigel Pharma (RIGL) to Offer Up to $40M in Common Stock
Oct 3, 2017 04:01PM Rigel Announces Proposed Public Offering Of Common Stock
Oct 3, 2017 10:00AM UPDATE: Rigel Pharmaceuticals (RIGL) PT Raised to $6 at BMO Capital; Fostamatinib Probability of Success Increases
Jun 19, 2017 09:20AM Rigel Pharmaceuticals (RIGL) PT Raised to $5 at BMO Capital; Tavalisse NDA Filing Accepted, Improves Probability of Success to 80%
Mar 8, 2017 06:04AM Rigel Pharma (RIGL) Reiterates Outperform Rating and $4 PT on Rigel Pharma (RIGL); 'Focused on Fostamatinib's Pending NDA Submission'
Feb 3, 2017 04:01PM Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
Jan 31, 2017 07:34AM Rigel Pharma (RIGL) Prices 20M Common Stock Offering at $2/Share
Jan 31, 2017 07:30AM Rigel Announces Pricing Of Public Offering Of Common Stock
Jan 30, 2017 04:02PM Rigel Pharma (RIGL) Plans Offering of Common Stock
Jan 30, 2017 04:01PM Rigel Announces Proposed Public Offering Of Common Stock
Jan 30, 2017 12:27PM Case for Rigel Pharmaceuticals (RIGL) Fostamatinib Approval Gets Stronger - BMO
Aug 30, 2016 08:21AM Rigel Pharmaceuticals (RIGL) PT Raised to $6 at BMO Capital Following Positive ITP Study
Aug 1, 2016 10:23AM Notable Analyst Rating Changes 8/1: (OAS) (QGEN) (DLTR) Upgraded; (HOG) (AIV) (CTXS) Downgraded
Aug 1, 2016 06:20AM BMO Capital Starts Rigel Pharmaceuticals (RIGL) at Outperform, $4 PT
Jun 4, 2013 10:39AM Notable Analyst Rating Changes 06/04: (SDRL) (ALTR) (TOL) Upgraded; (PVH) (RIGL) (CP) Downgraded
Apr 5, 2013 07:44AM BMO Capital Downgrades Rigel Pharmaceuticals (RIGL) to Market Perform
Oct 3, 2012 09:30AM Rigel (RIGL) Affirms Pricing 13.7M Offering at $9.50/Share
Oct 2, 2012 04:12PM Rigel Pharma (RIGL) Announces Common Offering
Sep 7, 2011 05:54PM BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform